Bone marrow transplantation for primary immunodeficiency diseases

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 207-237

  Szabolcs, Paul ^a,b   Cavazzana Calvo, Marina ^c,d   Fischer, Alain ^c   Veys, Paul ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Bone marrow transplantation; Hematopoietic stem cell transplantation; Primary immunodeficiency diseases; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE ZAP 70; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THYMOCYTE ANTIBODY; TREOSULFAN; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; AUTOSOMAL RECESSIVE DISORDER; BARE LYMPHOCYTE SYNDROME; BONE MARROW TRANSPLANTATION; CARTILAGE HYPOPLASIA; CELL SURVIVAL; CHEDIAK HIGASHI SYNDROME; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COLITIS; COMBINED IMMUNODEFICIENCY; COMORBIDITY; CONGENITAL DISORDER; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME DEFICIENCY; FOOD ALLERGY; GROWTH RETARDATION; HEMATOPOIESIS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HLA MATCHING; HUMAN; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INFECTION; INFERTILITY; INFLAMMATION; IPEX SYNDROME; LEUKOCYTE ADHESION DEFICIENCY; LIVING DONOR; LOW DRUG DOSE; LOW ENERGY RADIATION; MEMBRANE RECONSTITUTION; MORTALITY; MYCOBACTERIOSIS; NEUTROPENIA; OMENN SYNDROME; PURINE NUCLEOSIDE PHOSPHORYLASE DEFICIENCY; REDUCED INTENSITY CONDITIONING; REVIEW; SCHWACHMANN DIAMOND SYNDROME; SCLEROTHERAPY; SEVERE COMBINED IMMUNODEFICIENCY; SIBLING; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION; WISKOTT ALDRICH SYNDROME;

EID: 77951054600     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.12.004     Document Type: Review

References (154)

1. Bach F.H., Amos D.B. Hu-1: major histocompatibility locus in man. Science 1967, 156:1506-1508.
2. Gatti R.A., Meuwissen H.J., Allen H.D., et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 2:1366-1369.
3. Bach F.H., Albertini R.J., Joo P., et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968, 2:1364-1366.
4. Buckley R.H. A historical review of bone marrow transplantation for immunodeficiencies. J Allergy Clin Immunol 2004, 113:793-800.
5. Buckley R.H. Primary cellular immunodeficiencies. J Allergy Clin Immunol 2002, 109:747-757.
6. Buckley R.H. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000, 343:1313-1324.
7. Fischer A. Human primary immunodeficiency diseases: a perspective. Nat Immunol 2004, 5:23-30.
8. Geha R.S., Notarangelo L.D., Casanova J.L., et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007, 120:776-794.
9. Marodi L., Notarangelo L.D. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 2007, 7:851-861.
10. Boyle J.M., Buckley R.H. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007, 27:497-502.
11. Gluckman E., Rocha V. Cord blood transplantation: state of the art. Haematologica 2009, 94:451-454.
12. Kurtzberg J. Update on umbilical cord blood transplantation. Curr Opin Pediatr 2009, 21:22-29.
13. Griffith L.M., Cowan M.J., Kohn D.B., et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 2008, 122:1087-1096.
14. Pessach I., Walter J., Notarangelo L.D. Recent advances in primary immunodeficiencies: identification of novel genetic defects and unanticipated phenotypes. Pediatr Res 2009, 65(5 Pt 2):3R-12R.
15. Lagresle-Peyrou C., Six E.M., Picard C., et al. Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nat Genet 2009, 41:106-111.
16. Notarangelo L.D., Giliani S., Mazza C., et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev 2000, 178:39-48.
17. Buckley R.H. The multiple causes of human SCID. J Clin Invest 2004, 114:1409-1411.
18. Dadi H.K., Simon A.J., Roifman C.M. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med 2003, 349:1821-1828.
19. de Saint Basile G., Geissmann F., Flori E., et al. Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J Clin Invest 2004, 114:1512-1517.
20. Rieux-Laucat F., Hivroz C., Lim A., et al. Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. N Engl J Med 2006, 354:1913-1921.
21. Kung C., Pingel J.T., Heikinheimo M., et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med 2000, 6:343-345.
22. Shiow L.R., Roadcap D.W., Paris K., et al. The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol 2008, 9:1307-1315.
23. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004, 22:625-655.
24. Neven B., Leroy S., Decaluwe H., et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009, 113:4114-4124.
25. Sarzotti-Kelsoe M., Win C.M., Parrott R.E., et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood 2009, 114:1445-1453.
26. Elder M.E., Hope T.J., Parslow T.G., et al. Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency. Cell Immunol 1995, 165:110-117.
27. Arnaiz-Villena A., Timon M., Corell A., et al. Brief report: primary immunodeficiency caused by mutations in the gene encoding the CD3-gamma subunit of the T-lymphocyte receptor. N Engl J Med 1992, 327:529-533.
28. Villard J., Masternak K., Lisowska-Grospierre B., et al. MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore) 2001, 80:405-418.
29. Dror Y., Grunebaum E., Hitzler J., et al. Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology. Pediatr Res 2004, 55:472-477.
30. Buck D., Malivert L., de Chasseval R., et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell 2006, 124:287-299.
31. Buck D., Moshous D., de Chasseval R., et al. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol 2006, 36:224-235.
32. Villa A., Sobacchi C., Notarangelo L.D., et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood 2001, 97:81-88.
33. Antoine C., Muller S., Cant A., et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003, 361:553-560.
34. Gaspar H.B., Aiuti A., Porta F., et al. How I treat ADA deficiency. Blood 2009, 114(17):3524-3532.
35. Grunebaum E., Mazzolari E., Porta F., et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006, 295:508-518.
36. Kane L., Gennery A.R., Crooks B.N., et al. Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch Dis Child Fetal Neonatal Ed 2001, 85:F110-F113.
37. Myers L.A., Patel D.D., Puck J.M., et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002, 99:872-878.
38. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of haematopoietic stem cells and long term survival for primary immunodeficiencies in Europe: entering a new century, can we do better? submitted for publication.
39. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981, 2:327-331.
40. Ciceri F., Labopin M., Aversa F., et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008, 112:3574-3581.
41. Fernandes JFRV, Labopin M, et al. Comparison of outcomes of mismatched related stem cell and unrelated cord blood transplants in children with severe T-cell deficiencies. In Blood, Suppl; Abstract; 51st Annual meeting of the American Society of Hematology, New Orleans, LA, 2009.
42. Cavazzana-Calvo M., Carlier F., Le Deist F., et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007, 109:4575-4581.
43. Haddad E., Landais P., Friedrich W., et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998, 91:3646-3653.
44. Laffort C., Le Deist F., Favre M., et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 2004, 363:2051-2054.
45. Krenger W., Hollander G.A. The immunopathology of thymic GVHD. Semin Immunopathol 2008, 30:439-456.
46. Clave E., Busson M., Douay C., et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009, 113:6477-6484.
47. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006, 108:1797-1808.
48. Andre-Schmutz I., Le Deist F., Hacein-Bey-Abina S., et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002, 360:130-137.
49. Li Pira G., Kapp M., Manca F., et al. Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host. Curr Opin Immunol 2009, 21:549-556.
50. Satwani P., Cooper N., Rao K., et al. Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases. Bone Marrow Transplant 2008, 41:173-182.
51. Cavadini P., Vermi W., Facchetti F., et al. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest 2005, 115:728-732.
52. Grunebaum E., Bates A., Roifman C.M. Omenn syndrome is associated with mutations in DNA ligase IV. J Allergy Clin Immunol 2008, 122:1219-1220.
53. Loechelt B.J., Shapiro R.S., Jyonouchi H., et al. Mismatched bone marrow transplantation for Omenn syndrome: a variant of severe combined immunodeficiency. Bone Marrow Transplant 1995, 16:381-385.
54. Gomez L., Le Deist F., Blanche S., et al. Treatment of Omenn syndrome by bone marrow transplantation. J Pediatr 1995, 127:76-81.
55. Mazzolari E., Moshous D., Forino C., et al. Hematopoietic stem cell transplantation in Omenn syndrome: a single-center experience. Bone Marrow Transplant 2005, 36:107-114.
56. Nahum A., Reid B., Grunebaum E., et al. Matched unrelated bone marrow transplant for Omenn syndrome. Immunol Res 2009, 44:25-34.
57. Rossi G., Zecca M., Giorgiani G., et al. Non-myeloablative stem cell transplantation for severe combined immunodeficiency-Omenn syndrome. Br J Haematol 2004, 125:406-407.
58. Tsuji Y., Imai K., Kajiwara M., et al. Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team. Bone Marrow Transplant 2006, 37:469-477.
59. Jabado N., Le Deist F., Cant A., et al. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Pediatrics 1996, 98:420-428.
60. Klein C., Cavazzana-Calvo M., Le Deist F., et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood 1995, 85:580-587.
61. Saleem M.A., Arkwright P.D., Davies E.G., et al. Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child 2000, 83:356-359.
62. Godthelp B.C., van Eggermond M.C., Peijnenburg A., et al. Incomplete T-cell immune reconstitution in two major histocompatibility complex class II-deficiency/bare lymphocyte syndrome patients after HLA-identical sibling bone marrow transplantation. Blood 1999, 94:348-358.
63. Markert M.L. Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991, 3:45-81.
64. Grunebaum E., Zhang J., Roifman C.M. Novel mutations and hot-spots in patients with purine nucleoside phosphorylase deficiency. Nucleosides Nucleotides Nucleic Acids 2004, 23:1411-1415.
65. Carpenter P.A., Ziegler J.B., Vowels M.R. Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 17:121-124.
66. Baguette C., Vermylen C., Brichard B., et al. Persistent developmental delay despite successful bone marrow transplantation for purine nucleoside phosphorylase deficiency. J Pediatr Hematol Oncol 2002, 24:69-71.
67. Delicou S., Kitra-Roussou V., Peristeri J., et al. Successful HLA-identical hematopoietic stem cell transplantation in a patient with purine nucleoside phosphorylase deficiency. Pediatr Transplant 2007, 11:799-803.
68. Fagioli F., Biasin E., Berger M., et al. Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome. Bone Marrow Transplant 2003, 31:133-136.
69. Makitie O. Cartilage-hair hypoplasia in Finland: epidemiological and genetic aspects of 107 patients. J Med Genet 1992, 29:652-655.
70. Ridanpaa M., van Eenennaam H., Pelin K., et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 2001, 104:195-203.
71. Notarangelo L.D., Roifman C.M., Giliani S. Cartilage-hair hypoplasia: molecular basis and heterogeneity of the immunological phenotype. Curr Opin Allergy Clin Immunol 2008, 8:534-539.
72. Berthet F., Siegrist C.A., Ozsahin H., et al. Bone marrow transplantation in cartilage-hair hypoplasia: correction of the immunodeficiency but not of the chondrodysplasia. Eur J Pediatr 1996, 155:286-290.
73. Guggenheim R., Somech R., Grunebaum E., et al. Bone marrow transplantation for cartilage-hair-hypoplasia. Bone Marrow Transplant 2006, 38:751-756.
74. Notarangelo L.D., Miao C.H., Ochs H.D. Wiskott-Aldrich syndrome. Curr Opin Hematol 2008, 15:30-36.
75. Aldrich R.A., Steinberg A.G., Campbell D.C. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics 1954, 13:133-139.
76. Derry J.M., Ochs H.D., Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 79:922.
77. Lum L.G., Tubergen D.G., Corash L., et al. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med 1980, 302:892-896.
78. Filipovich A.H., Stone J.V., Tomany S.C., et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 2001, 97:1598-1603.
79. Ochs H.D., Filipovich A.H., Veys P., et al. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2008, 15:84-90.
80. Kobayashi R., Ariga T., Nonoyama S., et al. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Br J Haematol 2006, 135:362-366.
81. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008, 111:439-445.
82. Rao K., Amrolia P.J., Jones A., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005, 105:879-885.
83. Manis J.P., Alt F.W. Novel antibody switching defects in human patients. J Clin Invest 2003, 112:19-22.
84. Fasth A. Bone marrow transplantation for hyper-IgM syndrome. Immunodeficiency 1993, 4:323.
85. Gennery A.R., Khawaja K., Veys P., et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 2004, 103:1152-1157.
86. Holland S.M. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010, 38(1):3-10.
87. Seger R.A. Modern management of chronic granulomatous disease. Br J Haematol 2008, 140:255-266.
88. van den Berg J.M., van Koppen E., Ahlin A., et al. Chronic granulomatous disease: the European experience. PLoS One 2009, 4:e5234.
89. Seger R.A., Gungor T., Belohradsky B.H., et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002, 100:4344-4350.
90. Schuetz C., Hoenig M., Gatz S., et al. Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res 2009, 44:35-41.
91. Soncini E., Slatter M.A., Jones L.B., et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009, 145:73-83.
92. Bunting M., Harris E.S., McIntyre T.M., et al. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol 2002, 9:30-35.
93. Zimmerman G.A. LAD syndromes: FERMT3 kindles the signal. Blood 2009, 113:4485-4486.
94. Holland S.M. Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000, 2:1579-1590.
95. Al-Muhsen S., Casanova J.L. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008, 122:1043-1051. [quiz 1043--51].
96. Filipe-Santos O., Bustamante J., Chapgier A., et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006, 18:347-361.
97. Roesler J., Horwitz M.E., Picard C., et al. Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey. J Pediatr 2004, 145:806-812.
98. Roesler J., Kofink B., Wendisch J., et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 1999, 27:1368-1374.
99. Welte K., Zeidler C. Severe congenital neutropenia. Hematol Oncol Clin North Am 2009, 23:307-320.
100. Welte K., Zeidler C., Dale D.C. Severe congenital neutropenia. Semin Hematol 2006, 43:189-195.
101. Rosenberg P.S., Alter B.P., Link D.C., et al. Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol 2008, 140:210-213.
102. Elhasid R., Rowe J.M. Hematopoetic stem cell transplantation in neutrophil disorders: severe congenital neutropenia, leukocyte adhesion deficiency and chronic granulomatous disease. Clin Rev Allergy Immunol 2010, 38(1):61-67.
103. Rosenberg P.S., Alter B.P., Bolyard A.A., et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006, 107:4628-4635.
104. Choi S.W., Boxer L.A., Pulsipher M.A., et al. Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant 2005, 35:473-477.
105. Ferry C., Ouachee M., Leblanc T., et al. Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register. Bone Marrow Transplant 2005, 35:45-50.
106. Zeidler C., Welte K., Barak Y., et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood 2000, 95:1195-1198.
107. Vibhakar R., Radhi M., Rumelhart S., et al. Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome. Bone Marrow Transplant 2005, 36:855-861.
108. Myers K.C., Davies S.M. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant 2009, 15:279-292.
109. Bhatla D., Davies S.M., Shenoy S., et al. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant 2008, 42:159-165.
110. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007, 166:95-109.
111. Jordan M.B., Filipovich A.H. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant 2008, 42:433-437.
112. Horne A., Janka G., Maarten Egeler R., et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 2005, 129:622-630.
113. Baker K.S., Filipovich A.H., Gross T.G., et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2008, 42:175-180.
114. Eapen M., DeLaat C.A., Baker K.S., et al. Hematopoietic cell transplantation for Chediak-Higashi syndrome. Bone Marrow Transplant 2007, 39:411-415.
115. Kaplan J., De Domenico I., Ward D.M. Chediak-Higashi syndrome. Curr Opin Hematol 2008, 15:22-29.
116. Worth A., Thrasher A.J., Gaspar H.B. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol 2006, 133:124-140.
117. Sleight B.J., Prasad V.S., DeLaat C., et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant 1998, 22:375-380.
118. Bennett C.L., Ochs H.D. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr Opin Pediatr 2001, 13:533-538.
119. Baud O., Goulet O., Canioni D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001, 344:1758-1762.
120. Rao A., Kamani N., Filipovich A., et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007, 109:383-385.
121. Alousi A., de Lima M. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Clin Adv Hematol Oncol 2007, 5:560-570.
122. Barrett A.J., Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006, 20:1661-1672.
123. Rezvani A.R., Storb R. Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. Expert Opin Biol Ther 2008, 8:161-179.
124. Woolfrey A., Pulsipher M.A., Storb R. Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency. Curr Opin Pediatr 2001, 13:539-545.
125. Champlin R., Khouri I., Shimoni A., et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000, 111:18-29.
126. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
127. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
128. Amrolia P., Gaspar H.B., Hassan A., et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000, 96:1239-1246.
129. Veys P., Rao K., Amrolia P. Stem cell transplantation for congenital immunodeficiencies using reduced-intensity conditioning. Bone Marrow Transplant 2005, 35(Suppl 1):S45-S47.
130. Cohen J., Gandhi M., Naik P., et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005, 129:229-239.
131. Cohen J.M., Sebire N.J., Harvey J., et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007, 110:2209-2214.
132. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357-4363.
133. Shenoy S., Grossman W.J., DiPersio J., et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005, 35:345-352.
134. Jacobsohn D.A., Duerst R., Tse W., et al. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004, 364:156-162.
135. Horn B., Baxter-Lowe L.A., Englert L., et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006, 37:263-269.
136. Ozyurek E., Cowan M.J., Koerper M.A., et al. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 2008, 42:83-91.
137. Greystoke B., Bonanomi S., Carr T.F., et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 2008, 142:257-262.
138. Beelen D.W., Trenschel R., Casper J., et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 2005, 35:233-241.
139. Casper J., Knauf W., Kiefer T., et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004, 103:725-731.
140. Burroughs L.M., Storb R., Leisenring W.M., et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant 2007, 40:633-642.
141. Straathof K.C., Rao K., Eyrich M., et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 2009, 374:912-920.
142. Matthes-Martin S., Lion T., Haas O.A., et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003, 17:1934-1942.
143. Bradley M.B., Satwani P., Baldinger L., et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007, 40:621-631.
144. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003, 102:1915-1919.
145. Cooper N., Rao K., Gilmour K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006, 107:1233-1236.
146. Cooper N., Rao K., Goulden N., et al. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant 2008, 42(Suppl 2):S47-S50.
147. Vaughn G.B.J., Jordan M., Marsh R. Hematopoietic cell transplantation with reduced intensity conditioning (RIC HCT) for hemophagocytic lymphohistiocytosis (HLH) and X-linked lymphoproliferative syndrome. Histiocyte Society Meeting. Cambridge 2007, 20.
148. Pai S.Y., DeMartiis D., Forino C., et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006, 38:671-679.
149. Horwitz M.E., Barrett A.J., Brown M.R., et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001, 344:881-888.
150. Gungor T., Halter J., Klink A., et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005, 79:1596-1606.
151. Gungor T., Halter J., Stussi G., et al. Successful busulphan-based reduced intensity conditioning in high-risk paediatric and adult chronic granulomatous disease-The Swiss experience [abstract]. Bone Marrow Transplant 2009, 43:S75.
152. Suzuki N., Hatakeyama N., Yamamoto M., et al. Treatment of McLeod phenotype chronic granulomatous disease with reduced-intensity conditioning and unrelated-donor umbilical cord blood transplantation. Int J Hematol 2007, 85:70-72.
153. Qasim W., Cavazzana-Calvo M., Davies E.G., et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 2009, 123:836-840.
154. Burkholder T.H., Colenda L., Tuschong L.M., et al. Reproductive capability in dogs with canine leukocyte adhesion deficiency treated with nonmyeloablative conditioning prior to allogeneic hematopoietic stem cell transplantation. Blood 2006, 108:1767-1769.